Oclacitinib-13C-d3, a premium pharmaceutical research compound designed for advanced veterinary and immunology studies. As an isotopically labeled analog of Oclacitinib, it offers enhanced stability and precise isotopic tracking. Oclacitinib-13C-d3 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for inflammatory and allergic conditions in animals. Trusted by leading laboratories, Oclacitinib-13C-d3 is your go-to solution for cutting-edge veterinary and immunology research. Unlock new possibilities in the treatment of inflammatory and allergic disorders with Oclacitinib-13C-d3, where innovation meets reliability.
| Catalog Number | S000174 |
| Molecular Formula | C1413CH20D3N5O2S |
| Purity | 95% |
| IUPAC Name | N-methyl-1-[4-[7H-pyrrolo[2,3-d]pyrimidin-4-yl(trideuterio(113C)methyl)amino]cyclohexyl]methanesulfonamide |
| InChI | InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/i2+1D3 |
| InChIKey | HJWLJNBZVZDLAQ-JVXUGDAPSA-N |
| SMILES | [2H][13C]([2H])([2H])N(C1CCC(CC1)CS(=O)(=O)NC)C2=NC=NC3=C2C=CN3 |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |
